Loading clinical trials...
Loading clinical trials...
It is well known that incretin, particular GLP-１enhances satiety and reduces energy intake in controlling appetite and dietary in humans (Flint A, et al. Gutzwiller JP et al.). Recently, incretin-base...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Nagaoka Red Cross Hospital
NCT07581145 · Foot Ulcer Due to Type 2 Diabetes Mellitus
NCT07023406 · Type 2 Diabetes Mellitus (T2DM)
NCT06613854 · Type 2 Diabetes Mellitus (T2DM)
NCT06821399 · Diabetes, Diabetic Retinopathy, and more
NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
Nagaoka Red Cross Hospital
Nagaoka, Niigata
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions